Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher Wednesday after the company announced topline results from the Phase 2 SEISMiC study of istaroxime in early cardiogenic shock.
Istaroxime is a dual mechanism therapy designed to improve both systolic and diastolic cardiac function. The study met its primary endpoint in systolic blood pressure profile over six hours, with the istaroxime treated group performing "significantly better" than the control group.
